Free Trial

Structure Therapeutics (GPCR) Short Interest Ratio & Short Volume

Structure Therapeutics logo
$27.06 +0.08 (+0.30%)
As of 01/17/2025 04:00 PM Eastern

Structure Therapeutics Short Interest Data

Structure Therapeutics (GPCR) has a short interest of 10.75 million shares, representing 19.84% of the float (the number of shares available for trading by the public). This marks a 5.81% increase in short interest from the previous month. The short interest ratio (days to cover) is 13.0, indicating that it would take 13.0 days of the average trading volume of 770,004 shares to cover all short positions.

Current Short Interest
10,750,000 shares
Previous Short Interest
10,160,000 shares
Change Vs. Previous Month
+5.81%
Dollar Volume Sold Short
$291.54 million
Short Interest Ratio
13.0 Days to Cover
Last Record Date
December 31, 2024
Outstanding Shares
57,260,000 shares
Float Size
54,180,000 shares
Short Percent of Float
19.84%
Today's Trading Volume
846,835 shares
Average Trading Volume
770,004 shares
Today's Volume Vs. Average
110%
Short Selling Structure Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Structure Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

GPCR Short Interest Over Time

GPCR Days to Cover Over Time

GPCR Percentage of Float Shorted Over Time

Structure Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
12/31/202410,750,000 shares $291.54 million +5.8%19.8%13 $27.12
12/15/202410,160,000 shares $317.50 million -3.7%18.8%12.4 $31.25
11/30/202410,550,000 shares $349.73 million -6.1%19.5%13.4 $33.15
11/15/202411,230,000 shares $383.73 million +7.6%20.7%15.3 $34.17
10/31/202410,440,000 shares $429.61 million -3.3%19.1%15.6 $41.15
10/15/202410,800,000 shares $392.04 million +2.4%19.7%16.2 $36.30
9/30/202410,550,000 shares $463.04 million -0.1%19.3%14.1 $43.89
9/15/202410,560,000 shares $431.27 million +1.3%19.3%12.9 $40.84
8/31/202410,430,000 shares $397.70 million -6.9%19.0%12.3 $38.13
8/15/202411,200,000 shares $408.91 million +0.5%20.5%9.4 $36.51
7/31/202411,140,000 shares $416.52 million +0.3%21.3%9.6 $37.39
7/15/202411,110,000 shares $494.62 million +19.6%21.3%9.8 $44.52
6/30/20249,290,000 shares $364.82 million +32.0%18.1%9.1 $39.27
6/15/20247,040,000 shares $339.12 million +68.8%16.8%7.3 $48.17
5/31/20244,170,000 shares $142.61 million +1.5%10.0%4.5 $34.20
5/15/20244,110,000 shares $148.25 million -4.2%9.8%6.8 $36.07
4/30/20244,290,000 shares $169.20 million +4.4%10.4%7.4 $39.44
4/15/20244,110,000 shares $154.74 million +9.9%9.9%7.4 $37.65
3/31/20243,740,000 shares $160.30 million +15.4%9.0%6.4 $42.86
3/15/20243,240,000 shares $114.21 million +6.6%8.2%5 $35.25
2/29/20243,040,000 shares $123.33 million +21.6%7.4%3.4 $40.57
2/15/20242,500,000 shares $112 million +7.3%8.7%3 $44.80
1/31/20242,330,000 shares $101.63 million +5.0%7.0%2.5 $43.62
1/15/20242,220,000 shares $101.68 million -4.3%6.7%2.2 $45.80
12/31/20232,320,000 shares $94.56 million -31.2%7.0%2.2 $40.76
12/15/20233,370,000 shares $199.37 million +7.7%10.2%2.7 $59.16
11/30/20233,130,000 shares $174.31 million +17.7%9.6%3.3 $55.69
11/15/20232,660,000 shares $128.53 million -2.9%8.1%2.9 $48.32
10/31/20232,740,000 shares $203.58 million -3.2%7.9%3.3 $74.30
10/15/20232,830,000 shares $184.09 million -0.7%8.1%3.4 $65.05
9/30/20232,850,000 shares $143.70 million +24.5%8.2%3.8 $50.42
9/15/20232,290,000 shares $74.77 million -5.0%6.6%4.8 $32.65
8/31/20232,410,000 shares $67.94 million +6.6%6.8%6.3 $28.19
8/15/20232,260,000 shares $61.70 million -11.4%6.4%6.5 $27.30
7/31/20232,550,000 shares $93.92 million +8.5%6.7%9 $36.83
7/15/20232,350,000 shares $79.20 million +42.4%6.2%14.4 $33.70
6/30/20231,650,000 shares $68.59 million +63.4%4.4%11.8 $41.57
6/15/20231,010,000 shares $31.25 million +159.5%2.7%10.3 $30.94
5/31/2023389,200 shares $12.45 million +165.1%1.0%5.2 $32.00
5/15/2023146,800 shares $3.82 million No Change0.4%2.9 $26.00
Grab This Altcoin Before Trump's Crypto Announcement (Ad)

Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.


GPCR Short Interest - Frequently Asked Questions

What is Structure Therapeutics' current short interest?

Short interest is the volume of Structure Therapeutics shares that have been sold short but have not yet been closed out or covered. As of December 31st, traders have sold 10,750,000 shares of GPCR short. 19.84% of Structure Therapeutics' shares are currently sold short. Learn More on Structure Therapeutics' current short interest.

What is a good short interest ratio for Structure Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GPCR shares currently have a short interest ratio of 13.0. Learn More on Structure Therapeutics's short interest ratio.

Which institutional investors are shorting Structure Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Structure Therapeutics: Jane Street Group LLC, Walleye Capital LLC, and PEAK6 Investments LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Structure Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 19.84% of Structure Therapeutics' floating shares are currently sold short.

Is Structure Therapeutics' short interest increasing or decreasing?

Structure Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 10,750,000 shares, an increase of 5.8% from the previous total of 10,160,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Structure Therapeutics' float size?

Structure Therapeutics currently has issued a total of 57,260,000 shares. Some of Structure Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Structure Therapeutics currently has a public float of 54,180,000 shares.

How does Structure Therapeutics' short interest compare to its competitors?

19.84% of Structure Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Structure Therapeutics: Legend Biotech Co. (11.44%), Elanco Animal Health Incorporated (3.08%), Cytokinetics, Incorporated (12.07%), Nuvalent, Inc. (13.23%), Grifols, S.A. (1.44%), Viking Therapeutics, Inc. (17.47%), Axsome Therapeutics, Inc. (13.66%), TG Therapeutics, Inc. (18.50%), Krystal Biotech, Inc. (11.72%), Organon & Co. (7.14%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks.

What does it mean to sell short Structure Therapeutics stock?

Short selling GPCR is an investing strategy that aims to generate trading profit from Structure Therapeutics as its price is falling. GPCR shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Structure Therapeutics?

A short squeeze for Structure Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of GPCR, which in turn drives the price of the stock up even further.

How often is Structure Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GPCR, twice per month. The most recent reporting period available is December, 31 2024.




This page (NASDAQ:GPCR) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners